A big, bad business
点肥成金不现实
Medical firms struggle to profit from weight-loss treatments
制药公司试图从减肥治疗中获利
OBESITY is an epidemic to some and an opportunity to others.
肥胖症对某些人来说是传染病,对别的一些人来说则是机遇。
More than two-thirds of Americans are overweight.
超过三分之二的美国人已经超重。
Find a way to battle the bulge and a huge profit might be made.
找个办法和肥胖对抗,说必定就此大赚一笔。
On February 22nd one pharmaceutical firm, Vivus, took a small step towards this goal.
找个办法和肥胖对抗,说必定就此大赚一笔。
A committee advising America s Food and Drug Administration recommended that itapprove Vivus s diet drug, Qnexa.
2月22日,Vivus制药公司朝着这个目标前进了一步。给美国食品药物管理局做咨询的一家委员会推荐,Vivus公司的减肥药Qnexa。
However, the pill s long-awaited final approval may not come until April, if at all.
但是,如果获得批准,该药品的漫长的最终肯定直到四月份才会到来。
【2015考研英语阅读点肥成金不现实】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30